Easterseals announced that it received a $750,000 grant from the Abbott Fund to pilot the Project on Education and Community Health Equity. The grant will fund the project from now through 2025, with the three-year initiative aimed at addressing systemic barriers to high-quality education and healthcare experienced by children and families in underserved communities. According […]
Abbott
Another Medtronic HVAD recall is serious
A year after Medtronic ceded the LVAD market to Abbott, it has yet another Class I recall involving HeartWare Ventricular Assist Device pumps still implanted in patients. The FDA today designated a Medtronic recall involving the HVADs as Class I, the most serious level. It’s the second Class I recall designation for the HVADs this […]
Abbott presents positive data on MitraClip, TriClip heart implants
Abbott (NYSE:ABT) today announced late-breaking data supporting its MitraClip and TriClip structural heart solutions. Data for the MitraClip transcatheter edge-to-edge repair (TEER) device and the TriClip minimally invasive tricuspid heart valve repair device were presented at TVT: The Structural Heart Summit, the annual meeting from the Cardiovascular Research Foundation in Chicago. The company said in […]
The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions
For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space. Major players like Dexcom, Medtronic, Abbott and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table. The […]
Late-breaking data supports Abbott FreeStyle Libre 3 in 14-day glucose monitoring
Abbott (NYSE:ABT) announced data demonstrating the accuracy of its next-generation FreeStyle Libre 3 continuous glucose monitor (CGM). The latest version of the company’s FreeStyle Libre platform — designed as the smallest and thinnest CGM sensor in the world at the size of just two stacked U.S. pennies — picked up FDA clearance for people with diabetes aged […]
Abbott to develop biowearable for continuous monitoring of glucose, ketone levels
Abbott (NYSE:ABT) announced today that it is developing a new biowearable for continuously monitoring both glucose and ketone levels. The all-in-one sensor has already garnered FDA breakthrough device designation and will be used in pivotal trials in 2023, with regulatory submissions to follow thereafter. Get the full story at our sister site, Drug Delivery Business News.
FDA clears Abbott’s next-gen FreeStyle Libre 3 14-day CGM
Abbott (NYSE:ABT) announced today that it received FDA clearance for its next-generation FreeStyle Libre 3 continuous glucose monitor. FDA clearance for the latest iteration of the company’s FreeStyle Libre platform — designed as the smallest and thinnest CGM sensor in the world — covers use by people 4 years of age and older living with diabetes. […]
Abbott imaging catheter recall flagged as Class I by FDA
The FDA has identified the Abbott (NYSE:ABT) recall of its Dragonfly OpStar Imaging Catheter as a Class I recall. That’s the most serious level of a medical device recall, carrying the risk of serious injury or death. Five incidents, one injury and zero deaths were reported when Abbott initiated the recall on April 11. The […]
Abbott reports positive data on heart valve therapies
Abbott (NYSE:ABT) today announced clinical study data supporting its TriClip and Navitor heart valve treatment technologies. Data for the TriClip minimally invasive tricuspid heart valve repair device and Navitor next-generation transcatheter aortic valve implantation (TAVI) system were presented at the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EuroPCR). Real-world outcomes from the […]
Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection, […]
Abbott partners with Women as One to help more underrepresented clinicians lead trials
Abbott (NYSE:ABT) announced that it is working with Women as One to launch a new physician training program. The partnership aims to train more female and underrepresented physicians to pursue clinical trial research and to help recruit clinical trial participants from historically underrepresented groups. Women as One is a nonprofit organization with a mission to […]
